Results 31 to 40 of about 23,534 (120)

Challenging the Dogma: Reversal of End-Stage Liver Fibrosis with Tirzepatide in MASH Cirrhosis

open access: yesTransplantology
Background/Objectives: The growing prevalence of metabolic-associated steatotic liver disease (MASLD)/metabolic-associated steatohepatitis (MASH) is forecasted to be over 55% by 2040, representing a significant driver of cirrhosis and highlighting demand
Thuy-Duyen Nguyen   +3 more
doaj   +1 more source

Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists

open access: yesPharmaceuticals, 2022
Glucagon-like peptide-1 (GLP-1) is easily degraded by dipeptidyl peptidase-4 (DPP-4) in the human body, limiting its therapeutic effect on type II diabetes.
Lei Sun   +8 more
doaj   +1 more source

Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity

open access: yesObesity Facts, 2020
Objective: Hypothalamic obesity (HO) in children after treatment for a tumor in the suprasellar region has severe implications. Previous studies have shown various effects of glucagon-like peptide-1 (GLP-1) receptor agonist in acquired HO, but in adults ...
Jiska van Schaik   +6 more
doaj   +1 more source

Favorable Appendicular Skeletal Muscle Mass Changes in Older Patients With Type 2 Diabetes Receiving GLP-1 Receptor Agonist and Basal Insulin Co-Therapy

open access: yesClinical Medicine Insights: Endocrinology and Diabetes, 2023
Background And Aims: Maintaining appendicular skeletal muscle mass is important for maintaining the quality of life of elderly patients with type 2 diabetes. The possibility of GLP-1 receptor agonists for maintaining appendicular skeletal muscle mass has
Takafumi Osaka   +2 more
doaj   +1 more source

Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study

open access: yesThe Lancet. Healthy Longevity
Summary: Background: GLP-1 receptor agonists and SGLT2 inhibitors are increasingly being used in people with type 2 diabetes on the basis of findings from randomised clinical trials; however, little is known of whether clinical outcomes are affected by ...
ProfPhD Fei-Yuan Hsiao   +8 more
doaj   +1 more source

GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review

open access: yesEClinicalMedicine
Summary: Despite the availability of a wide range of antihypertensive agents, a significant proportion of individuals with resistant hypertension (RHTN) struggle to achieve blood pressure (BP) control.
Candace Jarade   +3 more
doaj   +1 more source

Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review

open access: yesQuality in Sport
: Obesity is a chronic and insidious disease that represents a significant global. The World Health Organization has announced that almost 60% of European adults are overweight or obese.
Michal Rabenda   +6 more
doaj   +1 more source

Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues

open access: yesMolecular Metabolism
Objectives: Unimolecular triagonists drive substantial weight loss in patients with obesity by engaging the glucagon-like peptide 1 receptor (GLP-1R) and glucose dependent insulinotropic polypeptide receptor (GIPR) to reduce food intake (FI) and the ...
Jonathan D. Douros   +24 more
doaj   +1 more source

Effects of GLP‐1 Receptor Agonists on Paediatric Population in a Real World Setting

open access: yesEndocrinology, Diabetes & Metabolism
Objective Incidence of type 2 diabetes mellitus (T2DM) and obesity is increasing in children. We aimed to observe the metabolic health effects of glucagon‐like peptide 1 (GLP‐1) receptor agonists in paediatric patients with T2DM in a real‐world setting ...
A. G. Barajas   +2 more
doaj   +1 more source

Targeting GLP-1 receptor trafficking to improve agonist efficacy

open access: yesNature Communications, 2018
Glucagon-like peptide-1 receptor (GLP-1R) promotes insulin secretion from pancreatic beta cells and undergoes agonist-mediated endocytosis. Here, authors study GLP-1R endocytosis caused by different agonists and show that a longer plasma membrane ...
Ben Jones   +20 more
doaj   +1 more source

Home - About - Disclaimer - Privacy